{"nctId":"NCT00885378","briefTitle":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","startDateStruct":{"date":"2009-05"},"conditions":["Type 2 Diabetes Mellitus"],"count":166,"armGroups":[{"label":"Saxagliptin plus metformin IR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Saxagliptin plus metformin IR"]},{"label":"Placebo plus metformin IR","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo plus metformin IR"]}],"interventions":[{"name":"Saxagliptin plus metformin IR","otherNames":["BMS-477118","Onglyza"]},{"name":"Placebo plus metformin IR","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* 18-78 years of age\n* Taking stable twice daily (BID) dosing of metformin IR (at least 1500 mg) for at least 8 weeks\n* A1C: 7-10%\n* C-peptide: ≥ 0.8 ng/mL\n* Body mass index (BMI): ≤45 kg/m\\^2\n\nExclusion Criteria:\n\n* Women of childbearing potential unable or unwilling to use acceptable birth control\n* Women who are pregnant or breastfeeding\n* Fasting plasma glucose (FPG) \\>270 mg/dL\n* Significant cardiovascular history\n* Symptoms of poorly controlled diabetes\n* History of diabetic ketoacidosis or hyperosmolar nonketotic coma\n* Insulin therapy within one year of screening\n* Cardiovascular even within the prior 6 months\n* New York Heart Association Stage III/IV congestive heart failure and/or known left ventricular ejection fraction \\<=40%\n* Significant history of renal or hepatic disease\n* History of a psychiatric disorder, alcohol or drug abuse within the previous year\n* Treatment with potent CYP3A4 inhibitors or inducers\n* Immunocompromised participants\n* Active liver disease or clinically significant abnormal hepatic, renal , endocrine, metabolic, or hematological screening tests","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Mean Baseline and Change From Baseline in Fasting Plasma Glucose (FPG)","description":"Mean change was adjusted for baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164.22","spread":"5.512"},{"groupId":"OG001","value":"161.25","spread":"4.624"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.73","spread":"4.51"},{"groupId":"OG001","value":"-4.22","spread":"4.20"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C < 7.0%) at Week 12","description":"Adjusted for baseline. Calculated using the method by Zhang et al. (Zhang M, Tsiatis A, Davidian M. Improving efficiency of inference in randomized clinical trials using auxiliary covariates. Biometrics. Published online on January 11, 2008; Digital Object Identifier: 10.1111/j.1541-0420.2007.00976.x.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"24.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C <= 6.5%) at Week 12","description":"Adjusted for baseline. Calculated using the method by Zhang et al. (Zhang M, Tsiatis A, Davidian M. Improving efficiency of inference in randomized clinical trials using auxiliary covariates. Biometrics. Published online on January 11, 2008; Digital Object Identifier: 10.1111/j.1541-0420.2007.00976.x.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participant Adverse Event (AE), Related AE, Serious Adverse Event (SAE), Related SAE, and Discontinued Due to AEs Summary","description":"AE = any new untoward medical occurrence/worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment.SAE = any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related=Possible, Probable, or Certain relationship to drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants With Reported Hypoglycemia AEs During Double-Blind Treatment Period","description":"Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants With Confirmed Hypoglycemia","description":"Confirmed hypoglycemia was defined by a fingerstick glucose value \\<= 50 mg/dL with associated hypoglycemia symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participant Electrocardiogram (ECG) Status at Baseline and Week 12","description":"Abnormal ECGs were defined as those not within the normal limits for the participant, according to the investigator. 'Shifted Normal to Abnormal' and 'Shifted Abnormal to Normal' references a change from measurements at Baseline to those at Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Baseline and Mean Change From Baseline in Participant Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)","description":"Baseline values reference the measurement for the cohort of participants evaluated at the given time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128.89","spread":"1.67"},{"groupId":"OG001","value":"127.57","spread":"1.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.99","spread":"1.07"},{"groupId":"OG001","value":"77.07","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"1.43"},{"groupId":"OG001","value":"0.17","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":"0.84"},{"groupId":"OG001","value":"0.95","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128.33","spread":"1.67"},{"groupId":"OG001","value":"127.60","spread":"1.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.87","spread":"1.08"},{"groupId":"OG001","value":"77.32","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"1.66"},{"groupId":"OG001","value":"-0.43","spread":"1.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.94"},{"groupId":"OG001","value":"0.86","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128.18","spread":"1.76"},{"groupId":"OG001","value":"127.38","spread":"1.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.85","spread":"1.13"},{"groupId":"OG001","value":"77.23","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"1.51"},{"groupId":"OG001","value":"0.83","spread":"1.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"0.75"},{"groupId":"OG001","value":"1.29","spread":"0.85"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Baseline and Mean Change From Baseline in Participant Heart Rate (HR)","description":"Baseline values reference the measurement for the cohort of participants evaluated at the given time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.45","spread":"1.072"},{"groupId":"OG001","value":"73.77","spread":"0.968"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"0.881"},{"groupId":"OG001","value":"1.18","spread":"0.778"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.51","spread":"1.091"},{"groupId":"OG001","value":"73.56","spread":"0.990"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":"0.914"},{"groupId":"OG001","value":"0.28","spread":"0.727"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.71","spread":"1.142"},{"groupId":"OG001","value":"73.55","spread":"1.035"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":"1.061"},{"groupId":"OG001","value":"0.60","spread":"0.866"}]}]}]},{"type":"PRIMARY","title":"Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12","description":"Mean change was adjusted for baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.92","spread":"0.11"},{"groupId":"OG001","value":"7.97","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"0.09"},{"groupId":"OG001","value":"-0.22","spread":"0.08"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Experiencing Changes From Baseline in Laboratory Parameters That Met the Marked Abnormality Criteria","description":"A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. ULN=upper limit of normal; LLN=lower limit of normal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Experiencing Changes From Baseline in Urinalysis Parameters That Met the Marked Abnormality Criteria","description":"Marked abnormality criteria were urine protein: if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4; urine blood: if pre-Rx=0, use \\>=2, if pre-Rx=0.5 or 1, use \\>=3, if pre-Rx=2, use \\>=4; Urine red blood cell count (RBC): if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4; urine white blood cell count (WBC): if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":86},"commonTop":[]}}}